New Psychoactive Substances Consumption in Opioid-Use Disorder Patients
Alías Ferri, María (Institut Hospital del Mar d'Investigacions Mèdiques)
Pellegrini, Manuela (Istituto Superiore di Sanità, Rome, Italy)
Marchei, Emilia (Istituto Superiore di Sanità, Rome, Italy)
Pacifici, Roberta (Istituto Superiore di Sanità, Rome, Italy)
Rotolo, Maria Concetta (Istituto Superiore di Sanità, Rome, Italy)
Pichini, Simona (Istituto Superiore di Sanità, Rome, Italy)
Pérez-Mañá, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Papaseit, Esther (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Muga, Roberto (Universitat Autònoma de Barcelona. Departament de Medicina)
Fonseca, Francina 1972- (Institut Hospital del Mar d'Investigacions Mèdiques)
Torrens, Marta (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Farré Albaladejo, Magí (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia

Data:	2022
Resum:	Background: Since the beginning of the 21st century, the large number and wide chemical variety of new psychoactive substances (NPS) that enter the market every year has become a public health problem. Given the rapidity with which the drug market is changing, many NPS are not clinically investigated and their effects and health risks are unknown. Drug testing is a very useful tool for this purpose, but, unfortunately, it is not very widespread in individuals with opioid-use disorder under detoxification treatment. The aim of this study is to investigate the use of illicit drugs and NPS in opioid-use disorder (OUD) patients on opioid agonist treatment. (2) Methods: A multicenter, descriptive, cross-sectional study was conducted at two addiction care services in Barcelona and Badalona, Spain. Urine samples were collected from OUD individuals attending these two centers, who anonymously donated a urine sample at the time of a periodical visit. Samples were analyzed by high-sensitivity gas chromatography-mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography-high -resolution mass spectrometry (UHPLC-HRMS). (3) Results: Out of the 187 collected and analyzed urine samples, 27. 3% were positive for any type of NPS and 8. 6% were positive for new synthetic opioids, including fentanyl and its derivatives (NSO). Other frequently detected substances were benzodiazepines in 46. 0% of samples, antipsychotics in 27. 8% of samples, or cocaine and cannabis in 23. 5% of samples. (4) Conclusion: A wide number of NPS, including NSO, have been detected in urine samples from an OUD population. A lack of NPS detection in standard drug screening among drug users can hide the identification of a potential public health problem.
Ajuts:	Instituto de Salud Carlos III PI17/01962 Instituto de Salud Carlos III PI20/00804
Nota:	Altres ajuts: Grant numbers RD21/0009/0001 and RD21/0009/0004, Gencat Suport Grups de Recerca, Grant Number: 2017 SGR 316 and 2017 SGR 530
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	New psychoactive substances ; Opioid-use disorder ; Urine sample analysis
Publicat a:	Biology, Vol. 11, Num. 5 (april 2022) , ISSN 2079-7737

DOI: 10.3390/biology11050645
PMID: 35625373

9 p, 282.8 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats